ANXA2 and cardiovascular disorder: ANXA2 may also mediate the effect of phosphate in cardiovascular diseases, which was supported by the findings that ANXA2 was downregulated in human endothelial cells in exposure to high phosphate media or to serum from hyperphosphatemic patients, and that blockade of membrane-ANXA2 with a specific neutralizing antibody mimicked the effects of high phosphate, such as impaired endothelial cell migration and tube formation (Di Marco et al., 2013).